The use of ibrutinib first line in younger patients, without 17p deletion or p53 mutation, has not yet been clearly demonstrated, one trial has reported an improvement in PFS and OS with ibrutinib and rituximab compared with FCR as a first-line treatment of CLL in patients under 70 [55]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.